Research Reference
Pinealon
Short peptide bioregulator studied for brain function
Research & educational purposes only. BioMaxFit does not sell, promote, or represent peptides in any way. We are strictly educational and recommend working with your doctor on anything health-related. The information below comes from published research and documents what has been studied, not what should be done. Many of these compounds are investigational and not approved by the FDA; possession or use outside an authorized clinical trial may be illegal in your jurisdiction. This is not medical advice.
Preclinical-Only — For Educational Purposes Only
This compound has no established human dosing. The information below documents preclinical (animal) findings and is provided for research and educational reference only. It is not medical advice or a dosing recommendation.
Pinealon is a short peptide bioregulator studied for brain function and pineal regulation in preclinical research. There is no established human dosing.
Reconstitution
Pinealon is a synthetic tripeptide (Glu-Asp-Pro) bioregulator developed in the Russian Federation and registered there. It is supplied as a lyophilized vial or pre-formulated solution for intramuscular/subcutaneous use. It is not FDA-approved in the United States.
No standardized human reconstitution protocol is established outside the CIS-region registered product. Compounded "research" forms sold online are not FDA-approved.
Cycling Protocol
Studied CIS-region protocols describe Pinealon administered in short courses (e.g., 5–10 injections over 1–2 weeks), sometimes repeated after an interval. No standardized long-term cycle is established; Pinealon is not FDA-approved and durations are community extrapolation.
Routes of Administration
Subcutaneous injection (studied route): Daily or alternate-day in short courses.
No oral route is established. Pinealon is not FDA-approved in the US.
Stacking Protocols
| Stack | Components | Purpose | | --- | --- | --- | | Cognitive bioregulator | Pinealon + Cortexin / Cerebrolysin | Combined CIS-region neuro-bioregulators (community) | | Sleep/circadian | Pinealon + Epitalon | Combined pineal bioregulators (community) |
Stacking combinations are community extrapolation. Pinealon is not FDA-approved.
Side Effects & Safety
- No human safety database in US frameworks — Pinealon is not FDA-approved and Western safety data is limited
- Injection-site reactions — possible
- Generally described as well-tolerated in the published CIS-region literature at studied doses
Pinealon is not FDA-approved in the United States. It is registered in some other countries. Compounded research-peptide forms are not FDA-approved.
Research Basis
Pinealon is a synthetic tripeptide (glutamyl-aspartyl-proline) bioregulator developed in the Russian Federation, in the peptide-bioregulator tradition.
Mechanism: Described as a tissue-specific epigenetic bioregulator targeting pineal gland function, melatonin regulation, and circadian rhythm; studied for cognitive and longevity effects.
Clinical evidence: Published CIS-region studies describe use in cognitive aging and sleep contexts, typically as short injection courses. Not FDA-approved in the US; Western trial data is limited.
Not FDA-approved in the US. Compounded research-peptide forms are sold for research purposes only.